 |
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Name: | Vancomycin Hydrochloride | Cas: | 1404-93-9 |
|---|---|---|---|
| Mf: | C66H76Cl3N9O24 | Purity: | 99% |
| Appearance: | White Powder | Package: | 1kg/bag Or 25kgs/drum |
| High Light: | Vancomycin Hydrochloride Pharmaceutical Ingredient,Vancomycin Hydrochloride HCl Powder,CAS 1404-93-9 Vancomycin HCl Powder |
||
Vancomycin HCl Powder Manufacturer Supplier Vancomycin Hydrochloride CAS 1404-93-9
Vancomycin is an antibiotic used to treat a number of bacterial infections.It is recommended intravenously as a first-line
treatment for complicated skin infections,bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistants. aureus. Blood levels may be measured to determine the correct dose.Vancomycin is also recommended by mouth as a treatment for severe Clostridium difficilecolitis. When taken by mouth it is very poorly absorbed.
| Product name | Vancomycin HCL |
| CAS No. | 1404-93-9 |
| MF | C66H76Cl3N9O24 |
| MW | 1485.71 |
| Purity | 99% |
| Appearance | White powder |
| Package | Aluminum Bag;Drums |
| Shelf life | 2 years |
Function
1. To narrow spectrum antibiotics effective only gram-positive bacteria, such as hemolytic streptococcus, pneumococcus, Neisseria gonorrhoeae and other enterococci are sensitive to resistant Staphylococcus aureus is especially sensitive to this product. The mechanism is to inhibit the synthesis of bacterial cell wall, which combines primary and bacterial cell wall, leaving certain amino acids can not enter in the cell wall glycopeptides. Penicillin-resistant S. aureus is mainly used for clinical caused by serious infections such as pneumonia, endocarditis.
2. Vancomycin is indicated for the treatment of serious, life-threatening infections by gram-positive bacteria unresponsive to other antibiotics. In particular, vancomycin should not be used to treat methicillin-sensitive Staphylococcus aureus because it is inferior to penicillins such as nafcillin.
3. Treatment of serious infections caused by susceptible organisms resistant to penicillins (Methicillin-resistant Staphylococcus aureus(MRSA) and multiresistant Staphylococcus epidermidis (MRSE)) or in individuals with serious allergy to penicillins.
| Adenosine | AR | 58-61-7 | ≥99% |
| Uridine | UR | 58-96-8 | ≥99% |
| Cytidine | CR | 65-46-3 | ≥99% |
| Xanthosine 5-monophosphate disodium salt | XMP- Na2 | 25899-70-1 | ≥98% |
| Inosine-5'-monophosphate disodium salt octahydrate | IMP- Na2 | 20813-76-7 | ≥98% |
| Adenosine 5′-monophosphate disodium salt | AMP- Na2 | 4578-31-8 | ≥98% |
| Adenosine 5'-Monophosphatesodiumsalt | AMP- Na | .13474-03-8 | ≥98% |
| 5-Adenylic acid | AMP | 61-19-8 | ≥98% |
| Adenosine 3',5'-cyclic monophosphate | Cyclic AMP,CAMP | 60-92-4 | ≥97% |
| Uridine 5-monophosphate, disodium salt | UMP- Na2 | 3387-36-8 | ≥98% |
| Uridine 5'-monophosphate | UMP | 58-97-9 | ≥98% |
| Cytidine 5''-monophosphate disodium salt | CMP- Na2 | .6757-06-8 | ≥98% |
| Cytidine 5′-monophosphate | CMP | 63-37-6 | ≥98% |
| Citicoline sodium | CDPC-Na | 33818-15-4 | ≥98% |
| uridine 5'-diphosphate disodium salt | UDP-Na2 | 27821-45-0 | ≥95% |
| IDP-K2 | ≥90% | ||
| Inosine-5'-diphosphoric acid disodium salt | IDP-Na2 | 54735-61-4 | ≥90% |
| Cytidine 5'-Diphosphate Trisodium Salt Hydrate | CDP-Na3 | 34393-59-4 | ≥90% |
| Cytidine-5'-diphosphate disodium salt | CDP-Na2 | 54394-90-0 | ≥90% |
| Adenosine 5'-diphosphate dipotassiuM salt | ADP-K2 | 114702-55-5 | ≥95% |
| Adenosine-5'-diphosphate, MonopotassiuM salt | ADP-K | 72696-48-1 | ≥95% |
| Adenosine-5-diphosphate disodium salt | ADP-Na2 | 16178-48-6 | ≥95% |
| Adenosine 5''-diphosphate sodium salt | ADP-Na | 20398-34-9 | ≥95% |
| Adenosine 5''-diphosphate | ADP | 58-64-0 | ≥95% |
| Uridine 5'-triphosphate disodium salt | UTP-Na3 | 19817-92-6 | ≥90% |
| Uridine-5'-triphosphoric acid trisodium salt | UTP-Na2 | 285978-18-9 | ≥90% |
| CTP-Na3 | ≥95% | ||
| Cytidine 5′-triphosphate disodium salt | CTP-Na2 | 36051-68-0 | ≥95% |
| Adenosine 5'-triphosphate disodium salt | ATP-Na2 | 987-65-5 | ≥95% |
| Adenosin-5'-triphosphat | ATP | 56-65-5 |
Contact Person: July
Tel: 25838890
